Evaluation of Apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates

We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -suseptible Staphylococcus aureus. Apramycin demonstrated an MIC50/MIC90 of 8/16 μg/mL. No strains had an MIC above the epidemiological cutoff value of 32μg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Source Type: research